Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%65 Equity-to-Asset is 0.71 as of Dec. 2025, which is 15% above its 10-year median of 0.62. GuruFocus rates CPHGF with a GF Score™ of 65/100 and a GF Value™ of $1.03 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 65.77% on this metric.
Consun Pharmaceutical Group (OTCPK:CPHGF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Consun Pharmaceutical Group Equity-to-Asset Related Terms
Consun Pharmaceutical Group Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Equity-to-Asset falls into.
Consun Pharmaceutical Group Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Consun Pharmaceutical Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a Equity-to-Asset of 0.71 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Consun Pharmaceutical Group and its competitors. This is 15% above median its historical median of 0.62. Over the past decade, Consun Pharmaceutical Group's Equity-to-Asset has ranged from 0.49 to 0.71. According to the industry distribution chart, Consun Pharmaceutical Group ranks #344 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 34.2%.
Is Consun Pharmaceutical Group's Equity-to-Asset too high?
Consun Pharmaceutical Group's current Equity-to-Asset of 0.71 is 15% above median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 0.71. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Consun Pharmaceutical Group's value of 0.71 is 18.3% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #344 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Consun Pharmaceutical Group has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #344 out of 1005 companies for Equity-to-Asset. This puts Consun Pharmaceutical Group in the upper half of its industry. The industry median Equity-to-Asset is 0.60. Consun Pharmaceutical Group's value of 0.71 is 18.3% above this benchmark. Historically, Consun Pharmaceutical Group's own Equity-to-Asset has ranged from 0.49 to 0.71 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 0.60, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Equity-to-Asset of 0.71 is 18.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Equity-to-Asset is 0.71, which is 15% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.03, compared to a current price of $1.80 — trading 74.8% above its estimated fair value. The current Equity-to-Asset is 0.71, which is 15% above median its 10-year median of 0.62 and 18.3% above the Drug Manufacturers industry median of 0.60. Consun Pharmaceutical Group's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Equity-to-Asset is 0.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 74.8% above its estimated GF Value™ of $1.03.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Equity-to-Asset: 0.71 (15% above median its 10-year median of 0.62)
GF Value™: $1.03 vs. price of $1.80 (74.8% above fair value)
Industry Position: 18.3% above the Drug Manufacturers median (#344 of 1005)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
65GF Score
Get the complete analysis for CPHGF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
